Wolfe Research Raises Corteva (NYSE:CTVA) Price Target to $86.00

Corteva (NYSE:CTVA) had its price target raised by research analysts at Wolfe Research from $81.00 to $86.00 in a report issued on Thursday,MarketScreener reports. The firm presently has an “outperform” rating on the stock. Wolfe Research’s price objective indicates a potential upside of 18.41% from the company’s previous close.

A number of other research analysts have also recently weighed in on CTVA. JPMorgan Chase & Co. cut shares of Corteva from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $75.00 to $77.00 in a research report on Thursday. Rothschild & Co Redburn reduced their target price on shares of Corteva from $71.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Citigroup upped their price target on shares of Corteva from $74.00 to $80.00 and gave the stock a “neutral” rating in a research report on Thursday. Weiss Ratings reissued a “hold (c-)” rating on shares of Corteva in a research report on Monday, December 29th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $88.00 target price on shares of Corteva in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $82.37.

Corteva Price Performance

Shares of Corteva stock opened at $72.63 on Thursday. The business’s fifty day moving average price is $68.82 and its 200 day moving average price is $68.42. Corteva has a twelve month low of $53.40 and a twelve month high of $77.41. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $49.08 billion, a P/E ratio of 45.97, a PEG ratio of 1.84 and a beta of 0.75.

Corteva (NYSE:CTVA) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 EPS for the quarter, hitting analysts’ consensus estimates of $0.22. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the business posted $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, research analysts anticipate that Corteva will post 2.96 earnings per share for the current year.

Hedge Funds Weigh In On Corteva

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC raised its holdings in Corteva by 307.2% in the fourth quarter. Brighton Jones LLC now owns 15,588 shares of the company’s stock valued at $888,000 after acquiring an additional 11,760 shares in the last quarter. Woodline Partners LP raised its stake in shares of Corteva by 40.3% in the 1st quarter. Woodline Partners LP now owns 57,919 shares of the company’s stock valued at $3,645,000 after purchasing an additional 16,644 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in shares of Corteva during the second quarter worth about $213,000. Maryland State Retirement & Pension System grew its stake in Corteva by 1.7% in the second quarter. Maryland State Retirement & Pension System now owns 33,251 shares of the company’s stock worth $2,478,000 after purchasing an additional 552 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Corteva by 2.9% in the second quarter. US Bancorp DE now owns 264,780 shares of the company’s stock valued at $19,735,000 after buying an additional 7,502 shares during the last quarter. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Corteva News Roundup

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Several sell‑side firms lifted targets and kept bullish ratings, signaling analyst confidence in longer‑term upside: Deutsche Bank to $90 (buy), Wolfe Research to $86 (outperform), and RBC to $89 (outperform). Deutsche Bank raise Wolfe Research raise RBC raise
• Positive Sentiment: Brokerage consensus remains constructive (consensus “Moderate Buy”), which supports demand for the shares despite near‑term noise. Consensus Moderate Buy
• Positive Sentiment: Strategic commentary highlights Corteva’s expanding role in global agriculture and technology leadership—positive for medium‑term growth expectations. Corteva expands role
• Neutral Sentiment: Analyst views are mixed across publications — some highlight long‑term upside tied to licensing and settlements, while others argue valuation limits near‑term gains. Investors should weigh catalyst timing. Bull case analysis Conflicting analyst views
• Neutral Sentiment: Technical analysis pieces warn of a key structural test — useful for traders but not definitive for fundamentals; could increase short‑term volatility. Technical caution
• Negative Sentiment: Q4 results missed revenue expectations (seasonal timing and weaker crop‑protection/seed demand); revenue miss and a wider loss drove an after‑hours selloff. Those operational misses are the main near‑term headwind. Q4 revenue miss After‑hours fall
• Negative Sentiment: JPMorgan downgraded Corteva from overweight to neutral (citing valuation/limited near‑term upside), which can cool momentum among institutional buyers. JPMorgan downgrade
• Negative Sentiment: Market reaction to the earnings miss (seasonal timing) and mixed guidance elements increases short‑term uncertainty even as analysts argue for longer‑term upside — expect higher intraday volatility. Seasonal timing impact

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.